KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $4.4 million.

  • CRISPR Therapeutics AG's Change in Accured Expenses rose 15631.85% to $4.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $44.9 million, marking a year-over-year increase of 26454.94%. This contributed to the annual value of $44.9 million for FY2025, which is 26454.94% up from last year.
  • CRISPR Therapeutics AG's Change in Accured Expenses amounted to $4.4 million in Q4 2025, which was up 15631.85% from $12.2 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Change in Accured Expenses ranged from a high of $43.0 million in Q1 2025 and a low of -$38.2 million during Q3 2024
  • In the last 5 years, CRISPR Therapeutics AG's Change in Accured Expenses had a median value of $2.9 million in 2021 and averaged $2.0 million.
  • In the last 5 years, CRISPR Therapeutics AG's Change in Accured Expenses surged by 204073.51% in 2022 and then plummeted by 25838.81% in 2025.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Change in Accured Expenses stood at $22.8 million in 2021, then tumbled by 236.5% to -$31.1 million in 2022, then soared by 70.44% to -$9.2 million in 2023, then rose by 14.59% to -$7.8 million in 2024, then soared by 156.32% to $4.4 million in 2025.
  • Its Change in Accured Expenses stands at $4.4 million for Q4 2025, versus $12.2 million for Q3 2025 and -$14.7 million for Q2 2025.